Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 81 entries
View as:

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05308901 Org: User:
Start: 08/02/22 End: 06/30/27 Due: 06/30/28

Chemoimmunotherapy and Radiation in Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01903083 Org: User:
Start: 07/31/13 End: 12/31/17 Due: 12/31/18

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Phase: N/A Priority: Normal
NCT ID: NCT04175834 Org: User:
Start: 02/05/20 End: 05/13/22 Due: 05/13/23

Angiotensin II Antagonism of TGF-Beta 1

Phase: N/A Priority: Normal
NCT ID: NCT00320970 Org: User:
Start: 08/31/02 End: 09/30/04 Due: 09/30/05

Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02688725 Org: User:
Start: 12/31/14 End: 12/31/19 Due: 12/31/20

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT02422381 Org: User:
Start: 07/20/15 End: 08/31/24 Due: 08/31/25

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT01909492 Org: User:
Start: 09/20/13 End: 10/05/23 Due: 10/05/24

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02117362 Org: User:
Start: 05/08/14 End: 11/28/18 Due: 11/28/19

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04373031 Org: User:
Start: 12/30/20 End: 06/30/25 Due: 06/30/26

A Trial of Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy

Phase: N/A Priority: Normal
NCT ID: NCT00892879 Org: User:
Start: 02/28/09 End: 12/31/10 Due: 12/31/11

Telemedicine Technology Demonstration Project for Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT02115620 Org: User:
Start: 03/23/14 End: 08/26/15 Due: 08/26/16

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Phase: N/A Priority: Normal
NCT ID: NCT04520711 Org: User:
Start: 02/08/22 End: 02/28/27 Due: 02/28/28

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Phase: N/A Priority: Normal
NCT ID: NCT06175000 Org: User:
Start: 03/13/24 End: 09/15/29 Due: 09/15/30

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01644968 Org: User:
Start: 11/30/03 End: 04/30/17 Due: 04/30/18

Comparison Study of Insulin Glargine and NPH Insulin

Phase: N/A Priority: Normal
NCT ID: NCT01854723 Org: User:
Start: 04/30/13 End: 12/31/15 Due: 12/31/16

Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00232206 Org: User:
Start: 05/31/05 End: 11/30/07 Due: 11/30/08

Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00850785 Org: User:
Start: 01/31/09 End: 05/31/12 Due: 05/31/13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02688712 Org: User:
Start: 03/24/16 End: 12/31/25 Due: 12/31/26

Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit

Phase: N/A Priority: Normal
NCT ID: NCT00996320 Org: User:
Start: 06/30/08 End: 06/30/09 Due: 06/30/10

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Phase: N/A Priority: Normal
NCT ID: NCT04334967 Org: User:
Start: 03/30/20 End: 05/27/22 Due: 05/27/23

Vaginal Delivery Debrief Checklist to Improve Team Communication

Phase: N/A Priority: Normal
NCT ID: NCT01822158 Org: User:
Start: 05/12/13 End: 12/31/13 Due: 12/31/14

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04417699 Org: User:
Start: 07/05/22 End: 02/21/24 Due: 02/21/25

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02559024 Org: User:
Start: 03/14/16 End: 10/31/18 Due: 10/31/19

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02575391 Org: User:
Start: 10/31/09 End: 09/30/12 Due: 09/30/13

Caring for the Whole Person

Phase: N/A Priority: Normal
NCT ID: NCT03034369 Org: User:
Start: 03/31/15 End: 12/31/17 Due: 12/31/18